<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124456">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02004873</url>
  </required_header>
  <id_info>
    <org_study_id>Micra</org_study_id>
    <nct_id>NCT02004873</nct_id>
  </id_info>
  <brief_title>Micra Transcatheter Pacing Study</brief_title>
  <official_title>Micra Transcatheter Pacing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm Disease Management</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm Disease Management</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>China: Ethics Committee</authority>
    <authority>China: China Food and Drug Administration  Czech Republic: Ethics Committee</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hong Kong: Ethics Committee</authority>
    <authority>Hungary: Scientific and Medical Research Council Ethics Committee</authority>
    <authority>Hungary : Competent Authority: EEKH Orvostechnikai Főosztály - Office of Health Authorisation and Administrative Procedures, Department of Medical Devices</authority>
    <authority>India: Central Drugs Standard Control Organization</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>India: Indian Council of Medical Research</authority>
    <authority>India: Institutional Review Board</authority>
    <authority>India: Ministry of Health  &amp; Welfare</authority>
    <authority>India: State Drug Control Authorities</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Japan: Institutional Review Board</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Malaysia: Institutional Review Board</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: Ministry of Health, Welfare and Sport</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Russia: The Ministry of Education and Science of the Russian Federation</authority>
    <authority>Serbia: Ethics Committee</authority>
    <authority>Serbia: Medicines and Medical Devices Agency</authority>
    <authority>Singapore: Domain Specific Review Boards</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and efficacy of the Micra
      Transcatheter Pacing System and to assess long term performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is expected to be conducted in up to 70 sites located around the world, including
      up to 35 sites in the United States (U.S.).Participating geographies may include countries
      such as the U.S, Europe, China, India, Malaysia, and Japan.

      Up to 780 subjects will be enrolled (i.e. consented) to allow up to 720 subjects to be
      implanted enabling at least 600 subjects to be followed for at least 12-months post-implant.

      There are two primary objectives in this study (one safety and one efficacy). The primary
      safety objective of the study is to evaluate major complications related to the Micra system
      or procedure. The primary safety endpoint will be evaluated at 6-months (183 days)
      post-implant. The primary efficacy objective, Micra pacing capture thresholds, will also be
      evaluated six months post-implant. This study also has a separate long term safety objective
      that will provide additional long-term safety data following potential regulatory
      submissions.

      All subjects will be followed until official study closure (official study closure is
      defined as when Medtronic and/or FDA requirements have been satisfied per the Clinical
      Investigational Plan and/or by a decision by Medtronic or regulatory authority).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major Complications</measure>
    <time_frame>Implant to 6 Months Post Implant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Micra system and/or procedure related major complication free rate 6-months post-implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pacing Capture Threshold Success</measure>
    <time_frame>6-Months Post Implant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pacing capture threshold (PCT) at the 6-month post-implant visit where success is defined as PCT &lt;=2 volts at 0.24 ms pulse width and the increase from implant is &lt;=1.5 volts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Micra Ventricular Capture Management (VCMT)</measure>
    <time_frame>6-Months Post Implant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects that have a VCMT that is within 0.5 Volts of the manual (auto decrement) PCT (0.24 ms pulse width) at the 6-month post-implant visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate Response</measure>
    <time_frame>3-Months and 6-Months Post Implant</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Micra sensor-indicated rate derived from the input of the accelerometer during the M-PREP treadmill test at the 3-month and 6-month follow-up visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Class I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National Guidelines</condition>
  <arm_group>
    <arm_group_label>Micra Pacemaker Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Micra Pacemaker Implant</intervention_name>
    <arm_group_label>Micra Pacemaker Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have a Class I or II indication for implantation of a single chamber
             ventricular pacemaker according to ACC/AHA/HRS 2008 guidelines and any national
             guidelines

          -  Subjects who are able and willing to undergo the study requirements and are expected
             to be geographically stable for the duration of the follow-up.

          -  Subjects who are at least 18 years of age (or older, if required by local law).

        Exclusion Criteria:

          -  Subjects who are entirely pacemaker dependent (escape rhythm &lt;30 bpm).

          -  Subject has an existing or prior pacemaker, ICD or CRT device implant.

          -  Subject has unstable angina pectoris or has had an acute myocardial infarction (AMI)
             in the 30 days prior to eligibility assessment.

          -  Subjects with current implantation of neurostimulator or any other chronically
             implanted device which uses current in the body. Note that a temporary pacing wire is
             allowed.

          -  Subjects with a mechanical tricuspid valve, implanted vena cava filter, or left
             ventricular assist device (LVAD).

          -  Subjects who are morbidly obese and physician believes telemetry communication of ≤5
             inches (12.7 cm) could not be obtained with programmer head.

          -  Subjects whose femoral venous anatomy is unable to accommodate a 23 French introducer
             sheath or implant on the right side of the heart (for example, due to obstructions or
             severe tortuosity) in the opinion of the implanter.

          -  Subjects who are considered as unable to tolerate an urgent sternotomy

          -  Subjects with a known intolerance to Nickel-Titanium (Nitinol) Alloy.

          -  Subjects for whom a single dose of 1.0mg dexamethasone acetate may be
             contraindicated.

          -  Subjects with a life expectancy of less than 12- months.

          -  Subjects who are currently enrolled or planning to participate in a potentially
             confounding drug or device trial during the course of this study. Coenrollment in
             concurrent trials is only allowed when document pre-approval is obtained from the
             Medtronic study manager.

          -  Pregnant women, or women of child bearing potential and who are not on a reliable
             form of birth control.

          -  Subjects with exclusion criteria required by local law (e.g. age, breast feeding,
             etc.).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight Reynolds</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Ritter</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Haut-Lévêque</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Micra Study Manager</last_name>
    <phone>800-328-2518</phone>
    <email>rs.micra@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407-1195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Science Center (OUHSC)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-5033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aurora Cardiovascular Services</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magyar Honvédség Honvédkorház</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CARE Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara - National Heart Institute</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis - Locatie Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Circulation's Pathology Agency on High Medical Technologies</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinicki Centar Srbije</name>
      <address>
        <city>Beograd</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital - University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pacemaker</keyword>
  <keyword>leadless</keyword>
  <keyword>single chamber</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
